National Center for Advancing Translational Sciences; Amended Notice of Meeting, 82386 [2023-25885]
Download as PDF
82386
Federal Register / Vol. 88, No. 225 / Friday, November 24, 2023 / Notices
The Agency received requests for
extension of the comment period for the
revised draft guidance. After
considering the requests, and in light of
the fact that the original comment
period is scheduled to close on
December 26, 2023, FDA has decided to
extend the comment period for the
revised draft guidance until January 5,
2024. The Agency believes that this
extension allows adequate time for
interested persons to submit comments
to ensure that FDA can consider the
comments before it begins work on the
final version of the guidance.
Dated: November 20, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–25969 Filed 11–22–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on HIV/AIDS
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice of a virtual meeting.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Service is hereby giving notice that the
Presidential Advisory Council on HIV/
AIDS (PACHA or the Council) will
convene the 79th full council meeting
utilizing virtual technologies on
Wednesday, December 6, 2023. The
meeting will be open to the public and
there will be a public comment session
during the meeting; pre-registration is
required to provide public comment. To
pre-register to provide public comment,
please send an email to PACHA@
hhs.gov and include your name,
organization, and title by close of
business Monday, November 27, 2023. If
you decide you would like to provide
public comment but do not pre-register,
you may submit your written statement
by emailing PACHA@hhs.gov by close of
business Wednesday, December 13,
2023. The meeting agenda will be
posted on the PACHA page on HIV.gov
at https://www.hiv.gov/federalresponse/pacha/about-pacha prior to
the meeting.
DATES: The meeting will be held on
Wednesday, December 6 from
approximately 11:00 a.m.–06:00 p.m.
(ET).
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
To attend the meeting
virtually, please visit www.hhs.gov/live.
ADDRESSES:
VerDate Sep<11>2014
21:46 Nov 22, 2023
Jkt 262001
Ms.
Caroline Talev, MPA, Senior
Management Analyst, at PACHA@
hhs.gov or Caroline.Talev@hhs.gov or
(202) 795–7622. Additional information
can be obtained by accessing the
Council’s page on the HIV.gov site at
www.hiv.gov/pacha.
SUPPLEMENTARY INFORMATION: PACHA
was established by Executive Order
12963, dated June 14, 1995, as amended
by Executive Order 13009, dated June
14, 1996 and is currently operating
under the authority given in Executive
Order 14048, dated September 30, 2021.
The Council was established to provide
advice, information, and
recommendations to the Secretary
regarding programs and policies
intended to promote effective HIV
diagnosis, treatment, prevention, and
quality care services. The functions of
the Council are solely advisory in
nature. The Council consists of not more
than 35 members. Council members are
selected from prominent community
leaders with particular expertise in, or
knowledge of, matters concerning HIV
and AIDS, public health, global health,
population health, philanthropy,
marketing or business, as well as other
national leaders held in high esteem
from other sectors of society. PACHA
selections also include persons with
lived HIV experience and racial/ethnic
and sexual and gender minority persons
disproportionately affected by HIV.
Council members are appointed by the
Secretary.
FOR FURTHER INFORMATION CONTACT:
Dated: October 31, 2023.
B. Kaye Hayes,
Deputy Assistant Secretary for Infectious
Disease, Director, Office of Infectious Disease
and HIV/AIDS Policy, Executive Director,
Presidential Advisory Council on HIV/AIDS,
Office of the Assistant Secretary for Health,
Department of Health and Human Services.
[FR Doc. 2023–25877 Filed 11–22–23; 8:45 am]
BILLING CODE 4150–43–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Center for
Advancing Translational Sciences
Special Emphasis Panel, Preclinical
Proof of Concept Studies for Rare
Diseases (R21) January 24, 2024, 9:00
a.m. to January 25, 2024, 5:00 p.m.,
National Institutes of Health, National
Center for Advancing Translational
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
Sciences, 6701 Democracy Boulevard,
Bethesda, MD, 20892 which was
published in the Federal Register on
November 14, 2023, FR DOC 2023–
25070, 88 FR 78052.
The meeting is being rescheduled due
to panel member availability. The
meeting will be held on February 1,
2024, 9:00 a.m. to February 2, 2024, 5:00
p.m. This meeting will be held virtually.
The meeting is closed to the public.
Dated: November 17, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–25885 Filed 11–22–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: December 20, 2023.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 903 South 4th Street, RML 31/3118,
Hamilton, MT 59840 (Virtual Meeting).
Contact Person: Kristin L. McNally, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 903
South 4th Street, RML 31/3118, Hamilton,
MT 59840 mcnallyk@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
E:\FR\FM\24NON1.SGM
24NON1
Agencies
[Federal Register Volume 88, Number 225 (Friday, November 24, 2023)]
[Notices]
[Page 82386]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25885]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Amended
Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Center for Advancing Translational Sciences Special Emphasis Panel,
Preclinical Proof of Concept Studies for Rare Diseases (R21) January
24, 2024, 9:00 a.m. to January 25, 2024, 5:00 p.m., National Institutes
of Health, National Center for Advancing Translational Sciences, 6701
Democracy Boulevard, Bethesda, MD, 20892 which was published in the
Federal Register on November 14, 2023, FR DOC 2023-25070, 88 FR 78052.
The meeting is being rescheduled due to panel member availability.
The meeting will be held on February 1, 2024, 9:00 a.m. to February 2,
2024, 5:00 p.m. This meeting will be held virtually. The meeting is
closed to the public.
Dated: November 17, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-25885 Filed 11-22-23; 8:45 am]
BILLING CODE 4140-01-P